Sartorius Acquires U.S. Start-up ViroCyt

Sartorius has acquired ViroCyt Inc., a U.S. start-up based in Broomfield, CO working in the field of rapid virus quantification, in a transaction valuing ViroCyt at approximately $16 million. ViroCyt is expected to achieve double-digit growth and generate more than $3 million sales in 2016.
 
ViroCyt’s main clients include pharma and biopharma R&D labs, vaccine manufacturers, as well as academia. The company’s automated platform, which integrates instruments, software and reagents, delivers high quality results faster than commonly used methods for virus counting.
 
Michael Melingo, member of the Sartorius Group Executive Committee, said, “After acquiring the cell screening specialist IntelliCyt, we are now adding a further very innovative bioanalytical tool to our Lab Products & Services portfolio that will enable our customers to obtain lab results much faster and reduce the time to clinic for virus-based pharmaceuticals.”
 
“Sartorius is an ideal partner for us due to its global presence and strong reputation for innovation and quality. By joining forces, we will drive further adoption of our novel approach to virus quantification both in the US and in international markets,” said Robert Kline, President and CEO of ViroCyt. He added that the acquisition by Sartorius is a very positive development for ViroCyt’s customers, employees and shareholders.